RESUMEN
In addition to the ability of G-CSF to stimulate the maturation and function of granulocytes, experimental and clinical evidence suggests that induction of leukemia cell differentiation may also be possible. This critical effect has received little attention with respect to its potential therapeutic application in myeloid malignancies. We describe the clinical course of a 62-year-old patient with atypical AML1/ETO-positive AML-M2 who repeatedly displayed a marked, dose-dependent response to G-CSF. He was originally investigated for neutropenia, but declined chemotherapy at diagnosis of AML (40% bone marrow blasts) and commenced G-CSF therapy when a life-threatening chest infection occurred. The bone marrow infiltration regressed and his blood counts normalized after 20 days. A slow relapse occurred over the next 3 months but a second hematological remission was achieved upon reintroduction of G-CSF. He remained well and free of transfusions for 2.5 years, receiving only maintenance G-CSF. Despite the presence of the AML1/ETO transcript, his leukemic blasts always failed to demonstrate the typical morphological, immunological and cytogenetic characteristics of AML1/ETO-AML of M2 subtype. He eventually developed resistance to G-CSF and died from sepsis after cytotoxic therapy. In selected AML cases differentiation therapy with growth factors may emerge as a useful antileukemic strategy, either alone or as an adjunct to established treatment modalities.
Asunto(s)
Proteínas de Unión al ADN/sangre , Proteínas de Unión al ADN/genética , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Leucemia Mieloide Aguda/terapia , Proteínas Proto-Oncogénicas/sangre , Proteínas Proto-Oncogénicas/genética , Factores de Transcripción/sangre , Factores de Transcripción/genética , Subunidad alfa 2 del Factor de Unión al Sitio Principal , Relación Dosis-Respuesta a Droga , Resultado Fatal , Humanos , Masculino , Persona de Mediana Edad , Proteínas Recombinantes , Inducción de RemisiónRESUMEN
The first case of oral hairy leukoplakia (OHL) in an HIV-negative 56-year-old patient with acute lymphocytic leukemia (ALL) is reported. A white plaque was observed while the patient was in complete remission which followed the chemotherapeutic scheme. The clinical and histopathologic findings were typical for OHL and the polymerase chain reaction method was positive for Epstein-Barr virus DNA. Underdiagnosis and underreporting of OHL in patients with a malignant haematological disease and the apparent different environmental factors to which these non-AIDS patients have been exposed, probably constitute some of the reasons for the very few OHL cases reported in these patients.
Asunto(s)
Atención Dental para Enfermos Crónicos , Leucoplasia Vellosa/complicaciones , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , ADN Viral/análisis , Seronegatividad para VIH , Herpesvirus Humano 4/genética , Humanos , Terapia de Inmunosupresión/efectos adversos , Leucoplasia Vellosa/etiología , Leucoplasia Vellosa/virología , Masculino , Persona de Mediana EdadRESUMEN
Adoptive immunotherapy with donor leukocytes has emerged as a promising strategy for the treatment of myeloma recurrence after allogeneic transplantation. 2.9 x 10(8)/kg donor mononuclear cells containing 1.4% CD34+ and 37% CD3+ cells were administered to a 48-year-old patient with non-secretory plasmablastic myeloma relapsing 9 months after a blood stem cell transplant from his HLA-identical sibling. In view of the extensive marrow infiltration and the aggressive behaviour of the disease, the donor cells were preceded by a course of EDAP chemotherapy. There was rapid clinical improvement, and CR was achieved on day 30 post infusion. However, three subcutaneous plasmacytomas showing anaplastic features developed within a few days. These failed to respond to interferon-alpha and continued to grow for 5 weeks in the absence of marrow plasmacytosis or other evidence of systemic disease. Grade 3 acute liver GVHD developed on day 79 which was controlled with immunosuppression. Overt systemic relapse occurred on day 90 as the GVHD came under control. The course of our case suggests highly proliferative malignant cells may escape the graft-versus-tumour effect of immunocompetent allogeneic cells in extramedullary sites subsequently resulting in overt systemic relapse if left untreated. New approaches are needed to deal with the problem of extramedullary disease recurrence.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Transfusión de Leucocitos , Mieloma Múltiple/terapia , Médula Ósea/patología , Enfermedad Injerto contra Huésped/inmunología , Humanos , Inmunoterapia Adoptiva , Interferón-alfa/uso terapéutico , Masculino , Persona de Mediana Edad , Mieloma Múltiple/inmunología , Mieloma Múltiple/patología , Recurrencia , Donantes de Tejidos , Trasplante HomólogoRESUMEN
This report presents data on visual evoked potentials (VEPs) and brainstem auditory evoked potentials (BAEPs), as well as neurologic, ophthalmologic and otologic assessments performed on 120 patients with beta-thalassemia major undergoing long-term DFO treatment. A total of 32 patients showed abnormal VEPs and 14 abnormal BAEPs; seven had both VEP and BAEP abnormalities; 12 had sensorineural hearing loss (SNHL); 18 had conductive hearing loss, while 14 showed a combination of SNHL and conductive hearing loss. After DFO administration was modified (taking in consideration the serum ferritin levels) patients with abnormal findings were retested. The values of 15 patients of 23 who underwent VEP examinations had been normalized. Eleven of 15 who repeated the BAEP test had also gained normal values. The audiogram had not returned to normal in any patient with SNHL. In a second repetition of the examinations, no change was observed. It is concluded that in a great percentage of thalassemics at least one of the above examinations shows abnormal values. These abnormalities are mostly reversible, and probably reflect a dysfunction of the visual or auditory system, due either to DFO neurotoxicity or to iron overload or both.
Asunto(s)
Deferoxamina/efectos adversos , Electroencefalografía/efectos de los fármacos , Potenciales Evocados Auditivos del Tronco Encefálico/efectos de los fármacos , Potenciales Evocados Visuales/efectos de los fármacos , Pérdida Auditiva Sensorineural/inducido químicamente , Transmisión Sináptica/efectos de los fármacos , Talasemia/fisiopatología , Adulto , Audiometría de Tonos Puros , Umbral Auditivo/efectos de los fármacos , Umbral Auditivo/fisiología , Transfusión Sanguínea , Tronco Encefálico/efectos de los fármacos , Tronco Encefálico/fisiopatología , Deferoxamina/administración & dosificación , Potenciales Evocados Auditivos del Tronco Encefálico/fisiología , Potenciales Evocados Visuales/fisiología , Pérdida Auditiva Sensorineural/diagnóstico , Pérdida Auditiva Sensorineural/fisiopatología , Homocigoto , Humanos , Transmisión Sináptica/fisiología , Talasemia/tratamiento farmacológico , Talasemia/genética , Trastornos de la Visión/inducido químicamente , Trastornos de la Visión/diagnóstico , Trastornos de la Visión/fisiopatología , Corteza Visual/efectos de los fármacos , Corteza Visual/fisiopatologíaRESUMEN
Because social policy favours the fullest possible social integration of chronically ill patients, we have evaluated the facilities that are needed to achieve this for patients with beta thalassaemia major in the light of the therapeutic advances that now permit them to survive into adulthood. We have investigated the social integration of adolescent and young adult thalassaemic patients, 171 from Greece and 112 from Ferrara in Italy. Patients in both areas show a good level of social integration and favourable self image, indicating what may be achieved by providing psychosocial support as part of a comprehensive approach to treatment.